Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8135155 | 0.94 | ADORA3 (0.40) | ADORA3TMIGD3MAPK1MAPTCYP3A4 | |
| SCHEMBL7864221 | 0.90 | ADORA3 (0.40) | ADORA3TMIGD3MAPK1MAPTCYP3A4 | |
| SCHEMBL8138174 | 0.89 | ADORA3 (0.36) | ADORA3TMIGD3MAPK1MAPTTSHR | |
| SCHEMBL7864187 | 0.87 | ADORA3 (0.39) | ADORA3TMIGD3MAPK1MAPTCYP3A4 | |
| SCHEMBL7876067 | 0.87 | ADORA3 (0.38) | ADORA3TMIGD3MAPK1MAPTCYP3A4 | |
| SCHEMBL7876032 | 0.85 | ADORA3 (0.41) | ADORA3TMIGD3MAPK1MAPTCYP3A4 | |
| SCHEMBL7871349 | 0.84 | ADORA3 (0.38) | ADORA3TMIGD3MAPK1MAPTCYP3A4 | |
| SCHEMBL7864225 | 0.84 | ADORA3 (0.41) | ADORA3TMIGD3MAPK1CYP3A4TSHR | |
| SCHEMBL7869604 | 0.84 | ADORA3 (0.40) | ADORA3TMIGD3MAPK1MAPTCYP3A4 | |
| SCHEMBL7864155 | 0.83 | ITGB1 (0.33) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306853-B1 | DICARBOXYLIC ESTER DERIVATIVES OF DIHYDROPYRIDINE COMPOUNDS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-10-23 | — | — | US | disclosed |